drugset / Trial / NCT05977465

Empagliflozin in Treatment of Peripheral Diabetic Neuropathy

NCT05977465

Phase 1/2 Completed 50 enrolled Tanta University
RandomizedParallel-groupOpen-labelTreatment

Summary

The aim of the study is to investigate the possible protective effect of empagliflozin in patients with type 2 diabetes mellitus with diabetic peripheral neuropathy and not on SGLT2 inhibitors treatment.

Timeline

Start
2022-01-20
Primary completion
2023-08-01
Completion
2023-08-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Empagliflozin Small molecule 25 mg